duchenne muscular dystrophy

News

Sarepta, Duchenne and gene therapy

2nd death reported in Sarepta gene therapy trial for Duchenne muscular dystrophy

Sarepta Therapeutics (NASDAQ:SRPT) reported a second fatality from acute liver failure in a patient treated with its gene therapy, Elevidys, designed for Duchenne muscular dystrophy (DMD), Bloomberg News reported Sunday.

· 1h

Sarepta reports second patient death after treatment with Duchenne gene therapy

BioPharma Dive · 1h

Second Duchenne patient dies after receiving Sarepta gene therapy

PMLive3h

Duchenne muscular dystrophy – diagnosis, clinical development and global research

Muscular dystrophy refers to a group of rare, genetic, progressive diseases that primarily affect the body’s muscles, causing ...

STAT1h

Lilly’s amylin candidate shows early promise

Supernus Pharmaceuticals said it is acquiring Sage Therapeutics, the distressed maker of a drug for postpartum depression, ...

EconoTimes5h

Roche Halts Elevidys Dosing in Some Duchenne Patients After Fatalities

Roche (SIX:ROG) shares dropped 2% on Monday after the company paused dosing of its gene therapy Elevidys in non-ambulatory ...

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...

3don MSN

Questions over cost of muscular dystrophy drug in Belfast Trust

The drug, Givinostat, has been approved as safe for use but Belfast Health Trust, NI's specialist centre for the condition, ...

Sarepta Shares Dive on Second Fatal Liver Failure Tied to Elevidys

Sarepta Therapeutics shares dived 42% in premarket trading after the company disclosed a second reported case of acute liver failure that resulted in a death tied to its Duchenne muscular dystrophy ...

Explore more

Sarepta

Elevidys

Results that may be inaccessible to you are currently showing.

Hide inaccessible results